Ganga Pharmaceuticals Ltd
Incorporated in 1989, Ganga Pharmaceuticals Ltd manufactures & trades in Pharmaceuticals & allied products (Ayurveda)[1]
- Market Cap ₹ 7.06 Cr.
- Current Price ₹ 14.6
- High / Low ₹ 19.6 / 9.25
- Stock P/E 353
- Book Value ₹ 13.2
- Dividend Yield 0.00 %
- ROCE 3.35 %
- ROE 0.37 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 1.10 times its book value
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- Promoter holding has decreased over last quarter: -5.11%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | |
|---|---|---|
| 3.08 | 2.37 | |
| 2.70 | 2.34 | |
| Operating Profit | 0.38 | 0.03 |
| OPM % | 12.34% | 1.27% |
| 0.17 | 0.25 | |
| Interest | 0.24 | 0.19 |
| Depreciation | 0.05 | 0.05 |
| Profit before tax | 0.26 | 0.04 |
| Tax % | 23.08% | 50.00% |
| 0.19 | 0.02 | |
| EPS in Rs | 0.47 | 0.05 |
| Dividend Payout % | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -23% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -89% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 6% |
| 3 Years: | 13% |
| 1 Year: | -33% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 0% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | |
|---|---|---|
| Equity Capital | 4.06 | 4.06 |
| Reserves | 1.29 | 1.31 |
| 1.45 | 1.55 | |
| 0.77 | 0.74 | |
| Total Liabilities | 7.57 | 7.66 |
| 0.76 | 0.72 | |
| CWIP | 0.00 | 0.00 |
| Investments | 0.09 | 0.09 |
| 6.72 | 6.85 | |
| Total Assets | 7.57 | 7.66 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | |
|---|---|---|
| -0.31 | -0.18 | |
| 0.37 | 0.28 | |
| -0.29 | -0.10 | |
| Net Cash Flow | -0.22 | 0.00 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | |
|---|---|---|
| Debtor Days | 126.80 | 126.29 |
| Inventory Days | 296.56 | 332.62 |
| Days Payable | 159.69 | 129.52 |
| Cash Conversion Cycle | 263.68 | 329.39 |
| Working Capital Days | 330.63 | 457.41 |
| ROCE % | 3.35% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s
2d - Board set 36th AGM on Sep 20, 2025; record closure Sep 14–20; secretarial auditor appointed for FY2025-26.
- Corporate Action - Fixes Book Closure For (AGM) 2d
-
Intimation For 36Th Annual General Meeting Scheduled To Be Held On Saturday, September 20, 2025.
2d - AGM Sept 20, 2025; cut-off Sep 13; remote e-voting Sep 17-19; books closed Sep 14-20.
-
Board Meeting Outcome for Held On Wednesday, August 20, 2025
2d - Board fixed 36th AGM on Sep 20, 2025; books closed Sep 14–20; appointed secretarial auditor for FY2025-26.
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 5 Aug
Annual reports
Concalls
-
May 2024TranscriptNotesPPT
Business Overview:[1]
GPL is engaged in production of quality Ayurvedic Medicines. Apart from manufacturing, the company is also into marketing and distribution of Ayurvedic Medicines